Chen Shuai, Wang Hongqi, Ning Bin
Department of Cardiovascular Medicine, Fuyang People's Hospital Affiliated to Anhui Medical University, Fuyang, China.
Front Cardiovasc Med. 2023 Oct 18;10:1234092. doi: 10.3389/fcvm.2023.1234092. eCollection 2023.
The objective of this study is to investigate the efficacy and safety of early ultrafiltration in patients with acute decompensated heart failure.
A systematic search was conducted on PubMed, Cochrane Library, and EMbase databases from inception to April 2023 to identify randomized controlled trials that compared the efficacy and safety of early ultrafiltration and conventional diuretics in patients with acute decompensated heart failure. Two investigators independently screened all eligible studies and extracted relevant data. The primary outcomes of interest were changes in body weight and creatinine levels, as well as the rate of readmission and mortality within 30 days. Meta-analysis was conducted using RevMan 5.4 software.
This meta-analysis included eight studies and found that early ultrafiltration was effective in reducing body weight in patients with acute decompensated heart failure ( = 1.45, 95% CI: 0.54-2.35, = 0.002), but it also increased serum creatinine ( = 0.1, 95% CI: 0.03-0.17, = 0.003). However, it did not reduce the 30-day rehospitalization rate or mortality rate (30-day rehospitalization rate: = 0.84, 95% CI: 0.62-1.14, = 0.28; Mortality: = 0.90, 95% CI: 0.57-1.44, = 0.67).
Although early ultrafiltration is more effective in reducing body weight in patients with acute decompensated heart failure, it is associated with an increase in serum creatinine levels and does not reduce the rate of readmission or mortality within 30 days.
identifier: CRD42023416152.
本研究旨在探讨早期超滤对急性失代偿性心力衰竭患者的疗效和安全性。
对PubMed、Cochrane图书馆和EMbase数据库从建库至2023年4月进行系统检索,以识别比较早期超滤与传统利尿剂对急性失代偿性心力衰竭患者疗效和安全性的随机对照试验。两名研究者独立筛选所有符合条件的研究并提取相关数据。感兴趣的主要结局包括体重和肌酐水平的变化,以及30天内再入院率和死亡率。使用RevMan 5.4软件进行荟萃分析。
该荟萃分析纳入八项研究,发现早期超滤在降低急性失代偿性心力衰竭患者体重方面有效( = 1.45,95%CI:0.54 - 2.35, = 0.002),但也会增加血清肌酐( = 0.1,95%CI:0.03 - 0.17, = 0.003)。然而,它并未降低30天再入院率或死亡率(30天再入院率: = 0.84,95%CI:0.62 - 1.14, = 0.28;死亡率: = 0.90,95%CI:0.57 - 1.44, = 0.67)。
尽管早期超滤在降低急性失代偿性心力衰竭患者体重方面更有效,但它与血清肌酐水平升高相关,且未降低30天内再入院率或死亡率。
标识符:CRD42023416152。